Eli Lilly's anti-obesity drug Ly3437943 is undergoing phase 3 clinical trials in Korea. The Ministry of Food and Drug Safety recently approved a phase 3 clinical trial to study the efficacy and safety of once-weekly administration of Retatrutide in obese or overweight type 2 diabetic subjects.

Seoul National University Hospital, Severance Hospital, Ulsan University Hospital, Hanyang University Guri Hospital, Korea University Ansan Hospital, and Yeungnam University Hospital participate in the phase 3 clinical trial conducted worldwide. Retatrutide is a triple agonist of Lilly's GIP/GLP-1/glucagon (GCG) receptor, which is famous as an obesity treatment following Mounjaro.

Mounjaro was clin